editasmedicine.com (EDIT) - Company Total Revenue

Corporate emblem and logo of editasmedicine.com (EDIT)

Editas Medicine, Inc. (EDIT) relies on scalable CRISPR systems with high margin potential. The company diversifies its risks by developing treatments for blood and vision disorders. However, the lack of revenue and high R&D expenses make the business dependent on clinical trials. The company's sales performance clearly demonstrates this stage of development, and the value of 0.05 captures this metric.

Editas Medicine, Inc. - EDIT Revenue and Sales Volume (period 07/04/2022 - 11/18/2026)

Comprehensive metric breakdowns and analytics for Editas Corp (EDIT)

Comprehensive company analysis:Editas Medicine, Inc. EDIT
Signature product of Editas

The indicator is based on daily revenue aggregation, capturing the actual cash inflow from product sales. This metric determines the financial stability of the business during periods of market downturns and cooling demand. For Editas Medicine, Inc. (EDIT), which focuses on R&D and production outsourcing, these data reflect the efficiency of patent monetization. Operational dependence on vendors makes this flow critically important. By analyzing the company's total sales volume, an investor assesses the real commercial viability of the biotechnological asset.

Key competitors

Tempus AI, Inc. (TEM) - Company Gross Revenue|Company Sales QGEN (Qiagen NV)|Revenue and Sales Volume Ionis Pharmaceuticals, Inc. (IONS)|Revenue and Sales Volume RGEN (Repligen Inc.)|Avidity Corp (RNA) - Company Total Revenue|CRSP - Company Revenue|Company Gross Revenue genedx.com WGS|Ultragenyx Pharmaceutical (RARE) - Company Revenue|Company Total Revenue Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Therapeutics) - Revenue and Sales Volume|Company Total Revenue Twist Bioscience Corp TWST|Revenue and Sales Volume TXG|Revenue and Sales Volume intelliatx.com (NTLA)|Stoke Therapeutics - Company Sales|BioLife Solutions Inc (BLFS) - Company Total Revenue|wavelifesciences.com - Revenue and Sales Volume|Maze Therapeutics Corp (MAZE) - Company Sales|SION: Revenue and Sales Volume|Company Sales Volume PRME|Company Revenue Taysha Gene Therapies|Company Sales Volume QURE (uniQure)|Company Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Sales Volume|Company Revenue Solid Biosciences SLDB|OCGN - Company Sales|pacb.com - Revenue and Sales Volume|Benitec (BNTC) - Company Sales|DSGN: Revenue and Sales Volume|RCKT - Company Gross Revenue|FDMT: Company Gross Revenue|Company Sales Volume LXEO (lexeotx.com)|Company Revenue Korro Bio Inc. (KRRO)|Silence Therapeutics plc - Company Sales Volume|Company Revenue ProQR Therapeutics N.V. PRQR|Company Gross Revenue Codexis, Inc. (CDXS)|SGMO - Company Revenue|nautilus.bio - Company Total Sales|Metagenomi, Inc (MGX) - Company Revenue|Company Sales Volume DTIL|Company Revenue Generation Bio|Revenue and Sales Volume Boundless Bio Inc|Company Revenue Exicure Corp (XCUR)|Company Gross Revenue Imunon|Revenue and Sales Volume PHIO (phiopharma.com)|Company Total Sales Volume mustangbio.com|RNAZ - Company Revenue|Company Total Revenue Bionano Genomics|APDN: Revenue and Sales Volume|Company Sales Volume BLUE|Company Sales IPA|OMGA: Company Sales Revenue|Revenue and Sales Volume OMIC|Company Gross Revenue Regulus Therapeutics|Company Revenue Syros SYRS|Company Sales Revenue TBIO|TCON: Company Sales|Unity Biotechnology, Inc. (UBX) - Company Sales